Whole genome sequencing of increased number of azithromycin-resistant Shigella flexneri 1b isolates in Ontario

Sci Rep. 2023 Oct 3;13(1):16582. doi: 10.1038/s41598-023-36733-w.

Abstract

Azithromycin (AZM) resistance among Shigella is a major public health concern. Here, we investigated the epidemiology of Shigella flexneri serotype 1b recovered during 2016-2018 in Ontario, to describe the prevalence and spread of AZM resistance. We found that 72.3% (47/65) of cases were AZM-resistant (AZMR), of which 95.7% (45/47) were among males (P < 0.001). Whole-genome based phylogenetic analysis showed three major clusters, and 56.9% of isolates grouped within a single closely-related cluster (0-10 ∆SNP). A single AZMR clonal population was persistent over 3 years and involved 67.9% (36/53) of all male cases, and none reported international travel. In 2018, a different AZMR cluster appeared among adult males not reporting travel. A proportion of isolates (10.7%) with reduced susceptibility to ciprofloxacin (CIP) due to S83L mutation in gyrA were AZM susceptible, and 71.4% reported international travel. Resistance to AZM was due to the acquisition of mph gene-bearing incFII plasmids having > 95% nucleotide similarity to pKSR100. Plasmid-borne resistance limiting treatment options to AZM, ceftriaxone (CRO) and CIP was noted in a single isolate. We characterized AZMR isolates circulating locally among males and found that genomic analysis can support targeted prevention and mitigation strategies against antimicrobial-resistance.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin* / pharmacology
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Bacterial / genetics
  • Dysentery, Bacillary* / drug therapy
  • Dysentery, Bacillary* / epidemiology
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Neisseria gonorrhoeae / genetics
  • Ontario / epidemiology
  • Phylogeny
  • Shigella flexneri / genetics
  • Whole Genome Sequencing

Substances

  • Azithromycin
  • Anti-Bacterial Agents
  • Ciprofloxacin